The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
Open accessAbstract
BACKGROUND: An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases. METHODS: We investigated the frequency of and risk factors associated with liver-related deaths in the Data Collection on Adverse Events of Anti-HIV Drugs study, which prospectively evaluated 76 893 person-years of follow-up in 23 441 HIV-infected persons. Multivariable Poisson regression analyses identified factors associated with liver-related, AIDS-related, and other causes of death. RESULTS: There were 1246 deaths (5.3%; 1.6 per 100 person-years); 14.5% were from liver-related causes. Of these, 16.9% had active hepatitis B virus (HBV), 66.1% had hepatitis C virus (HCV), and 7.1% had dual viral hepatitis co-infections. Predictors of liver-related deaths were latest CD4 cell count (adjusted relative rate [RR], 16.1; 95% confidence interval [CI], 8.1-31.7 for <50 vs > or =500/microL), age (RR, 1.3; 95% CI, 1.2-1.4 per 5 years older), intravenous drug use (RR, 2.0; 95% CI, 1.2-3.4), HCV infection (RR, 6.7; 95% CI, 4.0-11.2), and active HBV infection (RR, 3.7; 95% CI, 2.4-5.9). Univariable analyses showed no relationship between cumulative years patients were receiving cART and liver-related death (RR, 1.00; 95% CI, 0.93-1.07). Adjustment for the most recent CD4 cell count and patient characteristics resulted in an increased risk of liver-related mortality per year of mono or dual antiretroviral therapy before cART (RR, 1.09; 95% CI, 1.02-1.16; P = .008) and per year of cART (RR, 1.11; 95% CI, 1.02-1.21; P = .02). CONCLUSIONS: Liver-related death was the most frequent cause of non-AIDS-related death. We found a strong association between immunodeficiency and risk of liver-related death. Longer follow-up is required to investigate whether clinically significant treatment-associated liver-related mortality will develop.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Muñoz, A., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11913-1 · Cited by 1,099
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.-C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03232-3 · Cited by 894
Brinkman, K., Smeitink, J. A., Romijn, J. A., & Reiss, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06102-4 · Cited by 866
Soto, B., Sánchez-Quijano, A., Rodrigo, L., Olmo, J. A. D., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M. A., Rodríguez, M., Sales Gilabert, M., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80001-3 · Cited by 701
Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., & Lundgren, J. D. (2005) · AIDS · doi:10.1097/01.aids.0000163936.99401.fe · Cited by 569
Sterne, J. A., Hernán, M. A., Ledergerber, B., Tilling, K., Weber, R., Sendi, P., Rickenbach, M., Robins, J. M., & Egger, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67022-5 · Cited by 557
Predictors of patient and graft survival following liver transplantation for hepatitis C
Charlton, M., Seaberg, E., Wiesner, R., Everhart, J., Zetterman, R., Lake, J., Detre, K., & Hoofnagle, J. (1998) · Hepatology · doi:10.1002/hep.510280333 · Cited by 537
Qurishi, N., Kreuzberg, C., Lüchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., Rockstroh, J. K., & Spengler, U. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14844-1 · Cited by 525
Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30319 · Cited by 523
Hepatitis C and Progression of HIV Disease
Sulkowski, M. S. (2002) · JAMA · doi:10.1001/jama.288.2.199 · Cited by 445
Hepatitis C in the HIV-Infected Person
Sulkowski, M. S., & Thomas, D. L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00012 · Cited by 405
Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/432762 · Cited by 383
Lewden, C. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh307 · Cited by 373
Salmon-Ceron, D., Lewden, C., Morlat, P., Bévilacqua, S., Jougla, E., Bonnet, F., Héripret, L., Costagliola, D., May, T., & Chêne, G. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.01.022 · Cited by 319
Ledergerber, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16589-6 · Cited by 307
Mocroft, A., Brettle, R., Kirk, O., Blaxhult, A., Parkin, J. M., Antunes, F., Francioli, P., d'Arminio Monforte, A., Fox, Z., & Lundgren, J. D. (2002) · AIDS · doi:10.1097/00002030-200208160-00012 · Cited by 298
Rosenthal, E., Poirée, M., Pradier, C., Perronne, C., Salmon-Ceron, D., Geffray, L., Myers, R. P., Morlat, P., Pialoux, G., Pol, S., et al. (2003) · AIDS · doi:10.1097/00002030-200308150-00009 · Cited by 262
Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy
Núñez, M., Lana, R., Mendoza, J. L., Martín-Carbonero, L., & Soriano, V. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200108150-00002 · Cited by 251
Sabin, C. A., Smith, C. J., Gumley, H., Murphy, G., Lampe, F. C., Phillips, A. N., Prinz, B., Youle, M., & Johnson, M. A. (2004) · AIDS · doi:10.1097/00002030-200411050-00006 · Cited by 218
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus
Sulkowski, M. S., Mehta, S. H., Torbenson, M., Afdhal, N. H., Mirel, L., Moore, R. D., & Thomas, D. L. (2005) · AIDS · doi:10.1097/01.aids.0000163935.99401.25 · Cited by 177
Valdez, H., Chowdhry, T. K., Asaad, R. J., Woolley, I. J., Davis, T., Davidson, R. K., Beinker, N. K., Gripshover, B., Salata, R. A., McComsey, G. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/320164 · Cited by 153
Anderson, K. B., Guest, J. L., & Rimland, D. (2004) · Clinical Infectious Diseases · doi:10.1086/425360 · Cited by 144
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
Mocroft, A., Soriano, V., Rockstroh, J. K., Reiss, P., Kirk, O., Wit, S. D., Gatell, J. M., Clotet, B., Phillips, A. N., & Lundgren, J. D. (2005) · AIDS · doi:10.1097/01.aids.0000194799.43799.ea · Cited by 133
Mehta, S. H., Thomas, D. L., Torbenson, M. S., Brinkley, S., Mirel, L. B., Chaisson, R. E., Moore, R. D., & Sulkowski, M. (2005) · Hepatology · doi:10.1002/hep.20541 · Cited by 113
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
HIV Infection, Inflammation, Immunosenescence, and Aging
Deeks, S. G. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042909-093756 · Cited by 1,349
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Metadata
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-14
- Volume
- 166
- Issue
- 15
- Pages
- 1632
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W83931366
- Cited by
- 1,113
- References
- 31
- FWCI
- 44.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.